Skip to main content
Journal cover image

Design and Rationale of the pERSonalized cardIovascuLar dIsease prEvention, treatmeNt, and CarE (RESILIENCE) study.

Journal articles  - Clinical Trial, Journal Article
Rennyson, K; Kenjale, A; Chiswell, K; Li, Y; Uchehara, B; Armstrong, S; Goldstein, B; Kelsey, M; Hurdle, M; McGarrah, R; Nelson, AJ; Patel, M ...
Published in: Contemp Clin Trials
August 2026

BACKGROUND: Obesity is a growing epidemic associated with cardiovascular disease (CVD). The RESILIENCE study aimed to understand the factors underlying heterogeneity in CVD development among individuals with obesity as well as the variability in response to weight loss interventions in this population, with a focus on branched-chain amino acids (BCAA). METHODS: Four cohorts were recruited: individuals with obesity (BMI ≥ 30 kg/m2) and either high (≥20%) or low (<7.5%) 10-year atherosclerotic CVD (ASCVD) risk (calculated by the Pooled Cohorts Equation), and individuals with normal weight (BMI 18-25 kg/m2) and either high or low ASCVD risk. Clinical, behavioral, and molecular characteristics were collected at baseline between the four groups to assess heterogeneity between obesity and risk for CVD. Participants with obesity then participated in a 6-month remote weight loss intervention to evaluating predictors of response to the weight loss intervention. Our primary hypothesis was that BCAA are associated with CVD risk and obesity and that similarly, BCAA will predict response to weight loss interventions. RESULTS: 598 participants were recruited between 2019 and 2022 within the Duke University Health System. 100 had normal weight and low ASCVD risk, 103 had normal weight and high ASCVD risk, 196 patients had obesity and low ASCVD risk, and 199 patients had obesity and high ASCVD risk. CONCLUSIONS: This two-stage design (stratified baseline cohort with nested intervention) enables independent evaluation of the mechanisms linking obesity, CVD risk, and BCAA, among other variables. This approach will clarify how these factors influence cardiovascular disease variability and weight loss outcomes. TRIAL REGISTRATION: ClinicalTrials.gov (https://clinicaltrials.gov), NCT04551872.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Contemp Clin Trials

DOI

EISSN

1559-2030

Publication Date

August 2026

Volume

167

Start / End Page

108369

Location

United States

Related Subject Headings

  • Weight Reduction Programs
  • Weight Loss
  • Treatment Effect Heterogeneity
  • Research Design
  • Public Health
  • Obesity
  • Middle Aged
  • Male
  • Humans
  • Heart Disease Risk Factors
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Rennyson, K., Kenjale, A., Chiswell, K., Li, Y., Uchehara, B., Armstrong, S., … Pagidipati, N. J. (2026). Design and Rationale of the pERSonalized cardIovascuLar dIsease prEvention, treatmeNt, and CarE (RESILIENCE) study. Contemp Clin Trials, 167, 108369. https://doi.org/10.1016/j.cct.2026.108369
Rennyson, Katelyn, Aarti Kenjale, Karen Chiswell, Yanhong Li, Best Uchehara, Sarah Armstrong, Benjamin Goldstein, et al. “Design and Rationale of the pERSonalized cardIovascuLar dIsease prEvention, treatmeNt, and CarE (RESILIENCE) study.Contemp Clin Trials 167 (August 2026): 108369. https://doi.org/10.1016/j.cct.2026.108369.
Rennyson K, Kenjale A, Chiswell K, Li Y, Uchehara B, Armstrong S, et al. Design and Rationale of the pERSonalized cardIovascuLar dIsease prEvention, treatmeNt, and CarE (RESILIENCE) study. Contemp Clin Trials. 2026 Aug;167:108369.
Rennyson, Katelyn, et al. “Design and Rationale of the pERSonalized cardIovascuLar dIsease prEvention, treatmeNt, and CarE (RESILIENCE) study.Contemp Clin Trials, vol. 167, Aug. 2026, p. 108369. Pubmed, doi:10.1016/j.cct.2026.108369.
Rennyson K, Kenjale A, Chiswell K, Li Y, Uchehara B, Armstrong S, Goldstein B, Kelsey M, Hurdle M, McGarrah R, Nelson AJ, Patel M, Peterson ED, Roberts J, Truskey G, Douglas PS, Shah S, Pagidipati NJ. Design and Rationale of the pERSonalized cardIovascuLar dIsease prEvention, treatmeNt, and CarE (RESILIENCE) study. Contemp Clin Trials. 2026 Aug;167:108369.
Journal cover image

Published In

Contemp Clin Trials

DOI

EISSN

1559-2030

Publication Date

August 2026

Volume

167

Start / End Page

108369

Location

United States

Related Subject Headings

  • Weight Reduction Programs
  • Weight Loss
  • Treatment Effect Heterogeneity
  • Research Design
  • Public Health
  • Obesity
  • Middle Aged
  • Male
  • Humans
  • Heart Disease Risk Factors